Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
French National Agency for Research on AIDS and Viral Hepatitis Aventis Pharmaceuticals |
---|---|
Information provided by: | French National Agency for Research on AIDS and Viral Hepatitis |
ClinicalTrials.gov Identifier: | NCT00196651 |
HIV-specific immune responses are preserved in patients treated early during primary infection.The trial evaluated whether the addition to HAART of IL-2 alone or combined with an immunization procedure might enhance HIV immune responses and improve viral control after HAART discontinuation
Condition | Intervention | Phase |
---|---|---|
HIV Infection |
Drug: IL-2 Biological: LIPO-6T Biological: ALVAC VIH 1433 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Randomized Study on HIV Immune and Virological Responses Following the Administration of IL-2 Either Alone or Combined to ALVAC-HIV 1433 and HIV Lipopeptides (LIPO-6T) in Patients Treated Early With HAART During Primary Infection. ANRS 095 PRIMOVAC |
Estimated Enrollment: | 60 |
Study Start Date: | August 2000 |
Estimated Study Completion Date: | February 2004 |
HIV-specific immune responses are preserved in patients treated early during primary infection. The trial evaluated whether the addition to HAART of IL-2 alone or combined with an immunization procedure might enhance HIV immune responses and improve viral control after HAART discontinuation.Patients treated with HAART are randomized to 3 arms:arm1 HAART alone; arm2 with 5 cycles of IL-2 at wk0 ,8 ,16 ,24 and 32;arm3 4 injections of Alvac-HIV 1433 and LIPO-6T at wk0,4,8 followed by 3 cycles of IL-2 at w 16, 24 and 32. HAART is stopped at wk 40 in patient with undetectable plasma viral load. Viral loads and HIV-specific responses are monitored during the therapeutic period and after HAART interruption until w52. HAARTis rei-initiated with viral failure.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Principal Investigator: | Cecile Goujard, MD | Hopital Kremlin Bicetre Bicetre France |
Study Director: | Jean Pierre Aboulker, MD | Inserm SC10 France |
Study ID Numbers: | ANRS 095 PRIMOVAC |
Study First Received: | September 12, 2005 |
Last Updated: | September 12, 2005 |
ClinicalTrials.gov Identifier: | NCT00196651 |
Health Authority: | France: Afssaps - French Health Products Safety Agency |
HIV infection AIDS Vaccines ALVAC vaccine Interleukin-2 Antiretroviral Therapy, Highly Active |
Virus Diseases Sexually Transmitted Diseases, Viral Interleukin-2 HIV Infections |
Sexually Transmitted Diseases Acquired Immunodeficiency Syndrome Retroviridae Infections Immunologic Deficiency Syndromes |
Communicable Diseases RNA Virus Infections Slow Virus Diseases |
Immune System Diseases Lentivirus Infections Infection |